• Evaxion A/S EVAX.OQ reported a quarterly adjusted loss of 50 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of $1.50. The lone analyst forecast for the quarter was for a loss of 65 cents per share.

• Reported revenue was zero​; analysts expected $60.00 thousand.

• Evaxion A/S's reported EPS for the quarter was a loss of 50 cents​.

• The company reported a quarterly loss of $1.58 million.

• Evaxion A/S shares had risen by 1.6% this quarter and lost 55.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Evaxion A/S is $19.75

This summary was machine generated from LSEG data May 27 at 12:18 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)